Castle Biosciences raises 2026 revenue guidance to $365M-$375M as TissueCypher volume trends toward 50%-52% growth (NASDAQ:CSTL)
· seekingalpha.com
Castle Biosciences (CSTL) Q2 2026 earnings call recap: revenue up 20%, guidance raised, TissueCypher surging, margins/ASP risks.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...